AB T-Cell Receptor Engineered ;D T Cells Mediate Effective Antileukemic Reactivity

Retroviral transfer of T-cell receptors (TCR) to peripheral blood–derived T cells generates large numbers of T cells with the same antigen specificity, potentially useful for adoptive immunotherapy. One drawback of this procedure is the formation of mixed TCR dimers with unknown specificities due to pairing of endogenous and introduced TCR chains. We investigated whether ;D T cells can be an alternative effector population for TCR gene transfer because the ;DTCR is not able to form dimers with the ABTCR. Peripheral blood– derived ;D T cells were transduced with human leukocyte antigen (HLA) class I– or HLA class II–restricted minor histocompatibility antigen (mHag) or virus-specific TCRs. Because most ;D T cells do not express CD4 and CD8, we subsequently transferred these coreceptors. The TCR-transduced ;D T cells exerted high levels of antigen-specific cytotoxicity and produced IFN-; and IL-4, particularly in the presence of the relevant coreceptor. ;D T cells transferred with a TCR specific for the hematopoiesis-specific mHag HA-2 in combination with CD8 displayed high antileukemic reactivity against HA-2–expressing leukemic cells. These data show that transfer of ABTCRs to ;D T cells generated potent effector cells for immunotherapy of leukemia, without the expression of potentially hazardous mixed TCR dimers. (Cancer Res 2006; 66(6): 3331-7)